Consolidated Health economic evaluation reporting standards 2022 (CHEERS II) statement: a validated Dutch translation
CONCLUSION: Despite English being the common language of science, translating research instruments remains relevant to enhance clarity, accessibility, and inclusivity. The Dutch translation can be used by students, regulators, researchers or others to report and evaluate reporting of economic evaluations. Our detailed description of the applied methodology can facilitate future translations of research instruments.PMID:38400836 | DOI:10.1080/14737167.2024.2324048 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 24, 2024 Category: Health Management Authors: Amber Werbrouck Esther de Bekker-Grob Maiwenn Al Koen Putman Ruben Willems Source Type: research

Using real world evidence to optimize care: the case of medical cannabis
Expert Rev Pharmacoecon Outcomes Res. 2024 Feb 23:1-3. doi: 10.1080/14737167.2024.2322005. Online ahead of print.NO ABSTRACTPMID:38392352 | DOI:10.1080/14737167.2024.2322005 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 23, 2024 Category: Health Management Authors: Anne Katrin Schlag David J Nutt Michael Lynskey Source Type: research

Using natural language processing to analyze unstructured patient-reported outcomes data derived from Electronic Health Records for cancer populations: a systematic review
This study aimed to systematically review the published studies that used NLP techniques to extract and analyze PROs in clinical narratives from EHRs for cancer populations. We examined the types of NLP (with and without ML) techniques and platforms for data processing, analysis, and clinical applications.EXPERT OPINION: Utilizing NLP methods offers a valuable approach for processing and analyzing unstructured PROs among cancer patients and survivors. These techniques encompass a broad range of applications, such as extracting or recognizing PROs, categorizing, characterizing, or grouping PROs, predicting or stratifying ri...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 21, 2024 Category: Health Management Authors: Jin-Ah Sim Xiaolei Huang Madeline R Horan Justin N Baker I-Chan Huang Source Type: research

A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health?
Expert Rev Pharmacoecon Outcomes Res. 2024 Feb 19. doi: 10.1080/14737167.2024.2321244. Online ahead of print.NO ABSTRACTPMID:38372008 | DOI:10.1080/14737167.2024.2321244 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Alberto Raggi Matilde Leonardi Paolo Martelletti Source Type: research

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research

A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health?
Expert Rev Pharmacoecon Outcomes Res. 2024 Feb 19. doi: 10.1080/14737167.2024.2321244. Online ahead of print.NO ABSTRACTPMID:38372008 | DOI:10.1080/14737167.2024.2321244 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Alberto Raggi Matilde Leonardi Paolo Martelletti Source Type: research

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research

A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health?
Expert Rev Pharmacoecon Outcomes Res. 2024 Feb 19. doi: 10.1080/14737167.2024.2321244. Online ahead of print.NO ABSTRACTPMID:38372008 | DOI:10.1080/14737167.2024.2321244 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Alberto Raggi Matilde Leonardi Paolo Martelletti Source Type: research